![Mitchell Brigell](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Mitchell Brigell
Direttore Tecnico/Scientifico/R&S presso OCUPHIRE PHARMA, INC.
Profilo
Mitchell Brigell is currently the Vice President-Clinical Development at Aerpio Therapeutics, Inc. and the Head-Clinical Development & Strategy at Ocuphire Pharma, Inc. Previously, he held the position of Executive Director-Translational Medicine at Novartis Institutes of Biomedical Research from 2007 to 2013 and Vice President-Clinical Development at Aerpio Pharmaceuticals, Inc. from 2013 to 2019.
He also served as the Vice President-Americas Region at ISCEV.
Dr. Brigell holds a doctorate degree from Kansas State University.
Posizioni attive di Mitchell Brigell
Società | Posizione | Inizio |
---|---|---|
OCUPHIRE PHARMA, INC. | Direttore Tecnico/Scientifico/R&S | - |
Aerpio Therapeutics, Inc.
![]() Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | Direttore Tecnico/Scientifico/R&S | - |
Precedenti posizioni note di Mitchell Brigell
Società | Posizione | Fine |
---|---|---|
AERPIO PHARMACEUTICALS | Direttore Tecnico/Scientifico/R&S | 01/01/2019 |
Novartis Institutes of Biomedical Research
![]() Novartis Institutes of Biomedical Research BiotechnologyHealth Technology Novartis Institutes of Biomedical Research operates a pharmaceutical research organization. The private company is based in Emeryville. | Corporate Officer/Principal | 01/08/2013 |
ISCEV | Corporate Officer/Principal | - |
Formazione di Mitchell Brigell
Kansas State University | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
OCUPHIRE PHARMA, INC. | Health Technology |
Aziende private | 4 |
---|---|
Aerpio Therapeutics, Inc.
![]() Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | Health Technology |
Aerpio Pharmaceuticals, Inc.
![]() Aerpio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The firm's product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company was founded by Joseph H. Garder on November 16, 2007 and is headquartered in Cincinnati, OH. | Health Technology |
Novartis Institutes of Biomedical Research
![]() Novartis Institutes of Biomedical Research BiotechnologyHealth Technology Novartis Institutes of Biomedical Research operates a pharmaceutical research organization. The private company is based in Emeryville. | Health Technology |
ISCEV |
- Borsa valori
- Insiders
- Mitchell Brigell